Biomedical subjects

M Teran

Publications and source records attributed to M Teran.

4 recordsLinked to original sources

PubMed1992

Economic benefits of controlling internal and external parasites in South American camelids.

A trial was carried out in alpacas (Lama pacos) and llamas (Lama glama) to determine the economic benefits of controlling both external and internal parasites by the use of ivermectin ("Ivomec," Merck Sharp & Dohme). After four months the treated male alpacas gained on average 3.1 kg more than the untreated males, and their fleece weighed 0.36 kg more. The treated female alpacas gained 1.9 kg more than the controls, but their fleece weighed 0.03 kg less. This treatment gave a net financial benefit to the farmer of U.S. $3.54 for each of his male alpacas and U.S. $1.36 for each of his female alpacas. The results for the llamas were not significant because there was great variation in the weight gains (and losses). Because the value of llama fleece is less, the economic benefits were also less.

Animals↗

PubMed1992

Effects of parasitic infestation on the productivity of alpacas (Lama pacos).

A trial was carried out in alpacas (Lama pacos) to determine the economic benefit of controlling both external and internal parasites using ivermectin (Ivomec, Merck, Sharpe and Dohme). After four months the treated male alpacas had gained on average 3.1 kg more than the untreated males and their fleece weighed 0.36 kg more. Treated females gained 1.9 kg more than the controls but their fleece weighed 0.03 kg less. This resulted in a net financial benefit to the farmer of US$3.54 for each male alpaca and US$1.36 for each female.

Animal Husbandry↗

PubMed1990

Vaginal probes.

Explore the source record for details and available documents.

Animals↗

PubMedDate not supplied

Hepatitis C transmission through dialysis machines.

Hepatitis C virus antibodies (HCVAb) were studied in a total of 58 patients on chronic hemodialysis, all of whom were negative for Hepatitis B serology. The patients were evaluated by the second generation EIA test. Twenty-one of these patients, initially HCVAb(-), were dialyzed in unit A (UA), where no patients HCVAB(+) were ever dialyzed nor were patients with increased levels of serum transaminases, although they were HCVAb(-). Thirty-seven patients, also initially HCVAb(-), were dialyzed in unit B (UB), where they shared the same dialysis machines (DM) with 14 HCVAb(+) and 11 HCVAb(-) with elevated serum transaminases patients. Time on hemodialysis for UA patients was 30.95 +/- 10.74 months (range 14-52 months). In UB patients, time on dialysis was 28.46 +/- 17.33 months (range 4-78 months) (P = 0.554). The seroconversion for patients who were initially HCVAb(+) was: in UA, none became (+); and in UB, 17 patients became (+); Chi-square = 11.522 (P < 0.0001). Ten patients were transfused in UA and 23 in UB (Chi-square = 0.638; P = 0.424). In addition, 2.30 +/- 1.5 blood units were given to patients transfused in UA and 2.09 +/- 1.65 were given to patients transfused in UB (P = 0.733). This data indicates the existence of a route of vertical transmission from patient to patient through the DM, which would explain the differences between these two groups.

Adult↗